Association of circulating-free DNA mutation with response of targeted therapy in HER2-positive metastatic breast cancer.

Authors:

Abstract
E12083 Background: The addition of anti-HER2 targeted drug, like trastuzumab, lapatinib and TDM-1, to chemotherapy significantly improved prognosis of HER-2 positive breast cancer patients. However, it was confused that metastatic patients vary in the response of targeted drug. Therefore, methods of accurately predicting drug response were really needed. Because of the spatial and temporal limitations of needle core biopsies, we aimed to developing a higher sensitive and less invasive method of detecting mutations associated with drug response via circulating-free DNA (cfDNA) as a “liquid biopsy”. Methods: We developed a panel for detection of hotspot mutations from 50 oncogenes and tumor suppressor genes in 24 plasma samples of HER2-positive metastatic breast cancer patients who received systemic therapy from March 2014 to October 2015. Results: Totally 486 single nucleotide variants (SNV) from 46 genes were detected from 24 plasma samples. All samples harboured at least one mutation in this 50 genes panel (mean 20, range 1 to 51). Out of these 46 identified mutational genes, PIK3CA, KIT, TP53 were the top 3 mutated genes identified, with the prevalence of mutation 100%, 87.5%, 75%, respectively. And 18 genes’ mutational prevalence were under 20%. According to the treatment response about HER-2 targeted drug, 24 samples were divided into sensitive group (n = 8) and resistant group (n = 16). Comparing the SNV between two groups, we found nine gene that only occurred mutation in resistant group which was thought to be associated with targeted drug resistance. Particularly 7 samples have 11 SNVs from EGFR gene (7/16) with the mutation in exon 7, 18, 19, 20, respectively. In sensitive group, we detected a HER2 p.S855I mutation in two patients who have got long-term benefit from HER2 targeted drug. This HER2 gene mutation was probably associated with targeted drug long-term benefit. Conclusions: Targeted Next Generation Sequencing (NGS) of cfDNA has potential clinical utility to detect biomarker about HER2 targeted therapies.